[144] Health Catalyst, Inc SEC Filing

Rhea-AI Filing Summary

Health Catalyst, Inc. (HCAT) Form 144 shows a proposed sale of 8,335 shares of common stock through Morgan Stanley Smith Barney on 09/02/2025 on the NASDAQ, with an aggregate market value of $28,028.10. The filing reports the shares were acquired the same day (09/02/2025) as restricted stock from Health Catalyst as compensation. The filer previously sold 8,658 restricted shares on 06/02/2025 for gross proceeds of $31,470.10. The total number of outstanding shares is listed as 70,373,625. By signing, the seller represents no undisclosed material adverse information about the issuer.

Positive

• Proper disclosure: The filer formally reports the proposed sale and past sale as required under Rule 144
• Transaction details provided: Broker, dates, share counts, gross proceeds and acquisition nature are all disclosed

Negative

• Same-day acquisition and proposed sale: The 8,335 shares were acquired as restricted stock on 09/02/2025 and are listed for sale the same date
• No trading-plan date provided: The filing does not state adoption of a Rule 10b5-1 trading plan or instruction date

Insights

Securities Analyst

TL;DR: Routine insider sale notice; small share amount relative to outstanding stock, disclosed as required.

The filing documents a proposed sale of 8,335 shares via a broker on 09/02/2025 and notes those shares were granted as restricted stock and acquired the same day as compensation. The amounts and values reported are modest versus the 70,373,625 outstanding shares, suggesting limited near-term market impact. Recent past sale on 06/02/2025 of 8,658 shares for $31,470.10 is disclosed, showing prior disposition activity. This is a compliance-driven disclosure under Rule 144 rather than evidence of material company developments.

Corporate Governance Expert

TL;DR: Filing meets Rule 144 requirements; same-day grant and proposed sale are notable facts to monitor for insider trading policy alignment.

The form confirms the seller represents no undisclosed material information and records compensation-related restricted stock granted and proposed for sale on the grant date. From a governance perspective, the record of grant, prior sale, and broker usage indicates formal reporting compliance. The document does not include a trading plan date or additional context about any 10b5-1 plan, so no conclusions about pre-established instructions can be drawn from this filing alone.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC 1 New York Plaza, 38th Floor New York NY 10004	8335	28028.1	70373625	09/02/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/02/2025	Restricted Stock	Health Catalyst, Inc.			8335	09/02/2025	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Daniel Burton c/o 10897 South River From Parkway #300 South Jordan UT 84095	Restricted Stock	06/02/2025	8658	31470.1

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 for Health Catalyst (HCAT) disclose?

It discloses a proposed sale of 8,335 common shares via Morgan Stanley Smith Barney on 09/02/2025 with aggregate value $28,028.10

When and how were the shares acquired that are being sold?

The 8,335 shares were acquired on 09/02/2025 as restricted stock from Health Catalyst and listed as compensation

Has the filer sold Health Catalyst shares recently?

Yes. The filer sold 8,658 restricted shares on 06/02/2025 for gross proceeds of $31,470.10

How many Health Catalyst shares are outstanding according to the filing?

The filing lists 70,373,625 shares outstanding

Through which broker will the proposed sale be executed?

The broker listed is Morgan Stanley Smith Barney LLC, 1 New York Plaza, 38th Floor, New York, NY